A Patient with Corneal Epithelial Disorder That Developed after Administration of a Latanoprost Generic, but Not a Brand-Name Drug, Eye Drop
Background. We report a patient who developed corneal epithelial disorder repeatedly after changing the prescription from Xalatan eye drops (Pfizer Inc.) to Latanoprost eye drops (Kaken Pharmaceutical Co., Ltd.), both containing 0.005% latanoprost. Case Report. An 88-year-old male with glaucoma had...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Ophthalmological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/536746 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background. We report a patient who developed corneal epithelial disorder repeatedly
after changing the prescription from Xalatan eye drops (Pfizer Inc.) to Latanoprost
eye drops (Kaken Pharmaceutical Co., Ltd.), both containing 0.005% latanoprost.
Case Report. An 88-year-old male with glaucoma had been treated with Timoptol eye
drops and Xalatan eye drops for a few years. While he stayed in a health care
facility for the elderly, Xalatan eye drops was changed to Latanoprost eye drops
usage, and eye pain developed on the day of this change. On the next day, he visited
our department, and corneal epithelial disorder was observed. The drops were
discontinued, and the corneal epithelial disorder healed after 2 days. Twenty days after
the first consultation, Xalatan eye drops and Latanoprost eye drops were resumed
by a physician of internal medicine in the health care facility, but eye pain developed
again. After discontinuation of the two drugs, Xalatan eye drops usage was resumed
the next day, but no corneal epithelial disorder was observed thereafter.
Conclusions. This clinical history strongly suggested the association between a
generic drug, Latanoprost eye drops, and the development of corneal epithelial
disorder. |
|---|---|
| ISSN: | 2090-6722 2090-6730 |